AUSTIN, Texas — June 13, 2018— Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Mr. Chris Goulart has been appointed as Senior Vice President of Commercial Operations, a newly created position focusing on the Company’s growth operations.
“We warmly welcome Chris to the senior management team. We believe Chris’s role is core to our first-half 2018 investment in our commercial operations and our future growth now that OVA1 has ACOG endorsement, payer critical mass, and a 2018 PAMA rate,” stated Valerie Palmieri, President and CEO of Vermillion. “Chris’s global institutional and platform experience will be instrumental to driving growth and expanding our portfolio.”
Mr. Goulart has served in numerous Sales, Marketing & Business Development leadership roles during his career, most recently having served as the Director of Commercial Development at Natera, Inc., where he led the U.S. institutional sales efforts for Natera’s constellation product. Previously, Mr. Goulart was VP of Sales & Marketing for a genetics laboratory joint venture between Fresenius Medical Care and Shiel Holdings. Mr. Goulart also served as Director of International Sales & Managed Care for Recombine, which was acquired by Cooper Surgical. Prior to his role at Recombine, Mr. Goulart held various sales & sales leadership roles at Integrated Genetics (formerly Genzyme Genetics). Mr. Goulart started his career at Johnson & Johnson where he was a Territory Business Manager.
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has programs in gynecologic disease.
The company’s lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.aspirawh.com.
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, which involve significant risks and uncertainties, including statements regarding Mr. Goulart’s role and its effects on Vermillion’s growth [and portfolio]. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion’s expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements, including factors that are described in Vermillion’s Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.
Investor Relations Contact
Ashley R. Robinson
LifeSci Advisors, LLC